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Abstract
Background: Oesophageal cancer is a highly aggressive tumour entity with at present poor prognosis. Therefore,
novel treatment options are urgently needed. Hyaluronan (HA) is a polysaccharide present in the matrix of human
oesophageal squamous cell carcinoma (ESCC). Importantly, in vitro ESCC cells critically depend on HA synthesis to
maintain the proliferative phenotype. The aim of the present study is (1) to study HA-synthase (HAS) expression
and regulation in human ESCC, and (2) to translate the in vitro results into a mouse xenograft model of human
ESCC to study the effects of systemic versus tumour targeted HAS inhibition on proliferation and distribution of
tumour-bound and stromal hyaluronan.
Methods: mRNA expression was investigated in human ESCC biopsies by semiquantitative real-time RT PCR.
Furthermore, human ESCC were xenografted into NMRI nu/nu mice. The effects on tumour progression and
morphology of 4-methylumbelliferone (4-MU), an inhibitor of HA-synthesis, and of lentiviral knock down of HA-
synthase 3 (HAS3), the main HAS isoform in the human ESCC tissues and the human ESCC cell line used in this
study, were determined. Tumour progression was monitored by calliper measurements and by flat-panel detector
volume computed tomography (fpVCT). HA content, cellular composition and proliferation (Ki67) were determined
histologically.
Results: mRNA of HAS isoform 3 (HAS3) was upregulated in human ESCC biopsies and HAS3 mRNA was positively
correlated to expression of the epidermal growth factor (EGF) receptor. EGF was also proven to be a strong
inductor of HAS3 mRNA expression in vitro. During the course of seven weeks, 4-MU inhibited progression of
xenograft tumours. Interestingly, remodelling of the tumour into a more differentiated phenotype and inhibition of
cell proliferation were observed. Lentiviral knockdown of HAS3 in human ESCC cells prior to xenografting
mimicked all effects of 4-MU treatment suggesting that hyaluronan produced by ESCC is accountable for major
changes in tumour environment in vivo.
Conclusions: Systemic inhibition of HA-synthesis and knockdown of tumour cell HAS3 cause decreased ESCC
progression accompanied by tumour stroma remodelling and may therefore be used in novel approaches to ESCC
therapy.
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Oesophageal cancer is the sixth leading cause of cancer
deaths worldwide [1]. The mortality rate associated with
oesophageal cancer is similar to its incidence rate
because of its generally advanced stage at the time of
diagnosis, its aggressive characteristics, and because
of the paucity of effective treatment strategies. In spite
of its poor prognosis, oesophageal cancer has not been
well studied [2]. Two types of oesophageal cancer exist:
adenocarcinoma, and oesophageal squamous cell carci-
noma (ESCC), which corresponds to approximately 50%
of all oesophageal cancers. Standard treatment for oeso-
phageal cancer comprises surgery, chemoradiotherapy,
and palliative chemotherapy with cisplatin, fluorouracil,
and taxanes. However, the response to chemotherapy
typically lasts only a few months, and the median survi-
val time is less than one year [3]. Recent technical
advances in surgery, the use of neoadjuvant chemora-
diotherapy, and new cytotoxic drugs have increased the
response rates but have had no meaningful effect on
survival.
Hyaluronan (HA) is an unbranched high molecular
weight polysaccharide that is composed of D-glucuronic
acid beta(1-3)-D-N-acetyl-glucosamine beta(1-4). HA is
produced by three isoforms of the hyaluronan synthase
family (HAS1-3), which are located at the plasma mem-
brane and extrude the growing HA polymer into the
extracellular space [4]. Overexpression of either HAS2
or HAS3 in several tumour types such as prostate
cancer [5], breast cancer [6,7], osteosarcoma [8] and
colon carcinoma [9] is known to be associated with
higher malignancy or metastasis. The activity of all three
HAS isoenzymes can be inhibited by 4-methylumbelli-
ferone (4-MU), which depletes the activated uridine
diphosphate-glucuronic acid precursor pool and thus
leads to decreased HA production [10]. Recently, 4-MU
has been studied in different animal models and was
shown to inhibit liver metastases of melanoma cells
[11], to enhance chemotherapeutic action in pancreatic
and breast cancer cells [12,13] and to attenuate tumour
progression along with induction of apoptosis in pros-
tate cancer cells [14].
HA activates membrane receptors such as the receptor
of HA-mediated motility (RHAMM) and CD44 to
induce signalling and specific cellular responses. Both
CD44 and RHAMM have been implicated in tumour
cell biology and tumour progression [15].
An HA-rich matrix is important for a variety of
aspects of tumour pathobiology including anchorage-
independent growth, migration, angiogenesis, suppres-
sion of apoptosis [15,16] and metastasis [8,17].
Recently strong evidence for the importance of HA in
the microenvironment of tumours and in the tumour
stroma has been presented [18,19]. A variety of differ-
ent types of cancer are characterised by either high
amounts of tumour cell- associated HA (e.g., colon
and gastric cancer) or high amounts of stromal HA
(e.g., breast, ovarian, and prostate cancer) or both. In
some of these malignancies (e.g., colon cancer),
tumour-associated HA is an independent prognostic
factor for poor outcome [20]. In other tumours (e.g.,
ovarian and prostate cancer) it is the stromal HA that
is correlated with poor outcome, most likely because
of the accelerated growth of the tumours and their
metastases [4,21]. With respect to oesophageal cancer
it is has been demonstrated that HA accumulates in
the parenchyma and stroma [22].
The HA matrix of oesophageal carcinoma may contain
novel targets for therapeutic approaches such as the
HAS-isoforms, hyaluronidases and HA-receptors.
Furthermore, the role of individual HAS enzymes and
the factors that regulate HAS expression in oesophageal
cancer have not been defined. In addition, the relative
importance of stromal versus tumour cell HAS expres-
sion has not been addressed experimentally in any
cancer yet, which is due to the fact that HAS2 deficient
mice are lethal and HAS1 and HAS3 deficient mice are
not available to the scientific community [23].
Previously it was demonstrated in ESCC cell lines that
HA-synthesis mediated by HAS3, and to a lesser extent
by HAS2, is required for the malignant cell phenotype
characterised by filopodial plasma membrane extensions
and high proliferative activity [24]. Knockdown of HAS3
and inhibition of HA-synthesis by the small molecule
inhibitor, 4-MU, caused a rapid loss of focal contacts
which was followed by resolution of filopodia and inhi-
bition of proliferation and migration. Therefore, the aim
of the present study was to elucidate whether HAS iso-
forms are specifically upregulated in human ESCC
tumour specimens and if so whether inhibition of HA
synthesis would be effective to inhibit tumour growth
in vivo. Furthermore changes in tumour morphology
and distribution of HA and HA receptors, following
either systemic HA inhibition by 4-MU or inhibition of
tumour HA production by lentiviral knockdown of
HAS3, were examined. This approach may help to
define and specify the molecular targets and to explore
the therapeutic promises of pharmacologic HAS inhibi-
tion in ESCC.
Methods
Reagents and substances
Unless otherwise stated, all reagents were obtained from
Sigma-Aldrich, Munich, Germany. Erlotinib was bought
from LC Laboratories, Woburn. MA, USA. Cetuximab is
a product of Merck Serono, Darmstadt, Germany.
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OSC1 cells were a gift from M. Sarbia [25] and were
used for xenograft and cell culture experiments through-
out the present study. The human foreskin fibroblast
cell line Hs68 used in the co-culture experiments was
purchased from ATCC (Wesel, Germany). OSC1 and
Hs68 cells were maintained as monolayer cultures in
RPMI-1640 (Sigma-Aldrich) supplemented with 10%
fetal bovine serum, L-glutamine, penicillin, and strepto-
mycin at 37°C, 5% CO2 and 95% humidified air.
Human ESCC specimens
Tissue samples from oesophageal squamous cell carcino-
mas (ESSC, n = 20) and normal oesophageal mucosa (n =
13) were collected from patients undergoing radical en
bloc oesophagectomy at Düsseldorf University Hospital.
The tissues were snap-frozen in liquid nitrogen immedi-
ately after resection and stored in liquid nitrogen until use.
Written informed consent was obtained from all patients.
The collection of the fresh tumour samples was approved
by the ethics committee of the Heinrich Heine University
Düsseldorf. Tumour stage and grading were classified by
routine histopathologic assessment according to the UICC
(Union Internationale Contre le Cancer) Classification for
Malignant Tumours; the pathologists performing the
assessment were unaware of the experimental data.
Xenograft Model
NMRI nu/nu mice were used for subcutaneous tumour
formation experiments after xenografting of OSC1 cells
with or without previous lentiviral transduction in vitro.
The tumours were initiated by the subcutaneous injec-
tion of 10
6 OSC1 cells into both flanks, and the mice
were monitored after xenografting for 47 days in the 4-
MU group and 65 days in the shHAS3 group, respec-
tively. The mice were treated with 4-MU, which was
p e l l e t e di n t ot h ec h o w ,a t a daily dose of 250 mg per
mouse. Treatment started two days before xenografting.
Biopsies for immunostaining and molecular studies were
taken after sacrifice of the animals at the end of the
experiment. The animal experiments were approved by
the local animal facility and the Landesamt für Natur,
Umwelt und Verbraucherschutz, NRW.
Flat-Panel Detector Volume Computed Tomography
Imaging (fpVCT)
After an iodine-containing contrast agent (Isovist 300
®)
was injected intravenously, mice were subjected to
fpVCT, a nonclinical volume CT prototype (GE Global
Research, Niskayuna, NY), as described previously [26].
Immunostaining
Cryosections (8 μm) were derived from tumour tissue and
fixed in acetone-methanol (2:3) for the following
immunostaining: human cytokeratin 18 (Progen Biotech-
nik, Heidelberg, Germany; 1:200), alpha-smooth muscle
actin (Abcam; 1:50), secondary antibodies, goat anti-gui-
nea-pig-FITC, goat anti-rat-RhodX (Dianova, Hamburg,
Germany; 1:200), and sheep anti-rabbit-Cy3 (Sigma-
Aldrich; 1:200); biotinylated HABP was detected with Cy3-
labeled streptavidin (Dako; 1:200). Alternatively, fixation
with 96% ethanol was used for staining with rabbit anti-
human Ki67 (Abcam; 1:50) and rabbit anti- CD44 (Sigma-
Aldrich; 1:1000), which were detected with sheep anti-rab-
bit-IgG F(ab)2-Cy3 (Sigma-Aldrich; 1:50/1:500). HA was
detected by biotinylated HABP (Seikagaku, Tokyo, Japan;
6 μg/ml) and FITC- or Cy3-labeled streptavidin (Dako
Deutschland, Hamburg, Germany;1:200). Nuclei were
counterstained by Hoechst 33342 (Invitrogen, Karlsruhe,
Germany; 1:20000). Cell culture experiments were carried
out on glass cover slides, fixed with 3.7% formalin solution
and stained as above. Ki67 and HA staining were quanti-
fied by using ImageJ 1.37c software with the nucleus coun-
ter plug-in. For quantification five randomly selected
images from each tumour section were analyzed and the
average was used as n equals one.
Real-time RT-PCR
The PCR reactions were performed according to stan-
dard procedures with the SYBR Green PCR Master Mix
(Applied Biosystems). Relative expression levels were
compared by using real-time PCR with the 2
[-ΔΔC(T)]
method. The primer sequences of the genes of interest
are given in Table 1 [27,28].
Lentiviral knockdown of HAS3
The ESCC cell line, OSC1, was used for xenografting and
was maintained as described [25] in monolayer cultures.
HAS3 knockdown was achieved by using the MISSION™
Lentiviral shRNA knockdown system (Sigma-Aldrich).
The used hairpin sequence was 5’-CCGGGCTCTA-
CAACTCTCTGTGGTTCTCGAGAACCACAGAGAGT
TGTAGAGCTTT TTG-’3. A scrambled shRNA was used
as a control. The transfer into the packaging line HEK
293T (ATCC, LGC Standards, Wesel, Germany) was
Table 1 Primer sequences used for quantification of gene
expression
Gene Primer sequence
human EGFR 5’-GGA GAA CTG CCA GAA ACT GAC C-3’
5’-GCC TGC AGC ACA CTG GTT G-3’
human GAPDH 5’-GTGAAGGTCGGAGTCAACG-3’
5’-TGAGGTCAATGAAGGGGTC-3’
human HAS2 5’-GTGGATTATGTACAGGTTTGTGA-3’
5’-TCCAACCATGGGATCTTCTT-3’
human HAS3 5’-GAGATGTCCAGATCCTCAACAA-3’
5’-CCCACTAATACACTGCACAC-3’
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Grenzach-Wyhlen, Germany). After 16 h, the medium was
changed to Iscove’s Modified Dulbecco’sM e d i u m
(IMDM)forbetterstabilityoftheproduced lentiviralparti-
cles.Thenextday,thelentiviruseswereharvestedandcon-
centrated by centrifugation with poly-l-lysine under the
conditions reported previously [29]. After verification of
HAS3 mRNA knockdown by RT-PCR target cells were
transfected at a multiplicity of infection (MOI) of 10 and
kept for 5days innormal growth medium beforeinjection.
Statistical Analysis
Statistical analysis of mRNA levels in biopsy samples
was performed by using the nonparametric Mann-Whit-
ney test and the Spearman correlation analysis. All
other datasets were analyzed either by ANOVA and the
Bonferroni post hoc test or by Student’s t test as appro-
priate. Data are presented as means ± SEM. Statistical
significance was assigned at the level of p < 0.05.
Results
HAS3 is upregulated in human oesophageal SCC biopsies
and correlates with EGF receptor expression
We analysed the expression of HAS1-3 in human ESCC
tumours by RT-PCR and compared to healthy oesopha-
geal mucosa. HAS3 was the main isoform of the studied
ESCC tumour samples. This result is in accordance with
the HAS expression pattern found in the ESCC cell line
OSC1 as determined earlier [28]. Therefore, OSC1 cells
were used in this study for in vitro experiments and for
the xenograft model. In addition, only HAS3 expression
was significantly higher in ESCC than in normal mucosal
tissue whereas there was no significant increase regarding
HAS1 and HAS2 (data not shown). This result was true
over all studied samples (2.34+-0.5 fold induction vs.
control, mean+-SEM, p < 0.05) as well as for the T = 1
(3.15+-1.2 fold induction vs. control, mean+-SEM, p <
0.05) and the T = 2-4 (1.81+-0.3 fold induction vs. con-
t r o l ,m e a n + - S E M ,p<0 . 0 5 )subgroups according to
TNM classification (defining tumour size (T), lymph
node involvement (N) and existence of metastases (M))
(Figure 1A). Furthermore, the mRNA levels of HAS3
were positively correlated with the mRNA levels of EGF
receptor (HER1, ErbB1) in tumour cells, but no correla-
tion between these mRNA levels was observed in normal
mucosa (Figure 1B, C). Interestingly, T1 grade tumour
samples showed a steeper correlation than did T2-4. This
might indicate a stronger dependence of early tumour
grades on EGF pathway signalling to maintain HAS3
activity. In line with these findings, EGF receptor activa-
tion led to induction of HAS3 in ESCC cells, which could
be rescued by use of the EGF receptor tyrosine kinase
inhibitor erlotinib and the monoclonal anti-EGFR anti-
body cetuximab (Figure 1D).
4-MU inhibits tumour growth in vivo and causes tumour-
stroma remodelling
A xenograft tumour model was established by subcuta-
neously injecting the human ESCC line OSC1 into the
flanks of NMRI nu/nu mice. The mice were given oral
doses of the small molecule HAS inhibitor 4-MU start-
ing 2 days before injection for the whole experimental
period. During the first 47 days after xenografting calli-
per measurements showed that treatment with 4-MU
strongly inhibited the time course of tumour progres-
sion (Figure 2A). At the end of the experimental period
additional analysis using flat-panel volume computed
tomography (fpVCT) revealed also significantly lower
tumour volumes (control 100 ± 20,0% vs. 4-MU 27,4 ±
11,8%, Figure 2B).
Treatment with 4-MU not only was associated with
decreased tumour size but also caused remarkable
alterations in tumour morphology. Histopathological
examination of tumour specimens from control mice
showed that OSC1-derived xenograft tumours were
poorly differentiated, with numerous loosely cohesive
tumour cells (Figure 2C, left). In contrast, tumours from
mice treated with 4-MU were characterised by the for-
mation of distinct tumour cell clusters and large contin-
uous areas of intratumoural stroma, as indicated by
alpha-smooth muscle actin staining (Figure 2D, right).
The outer circumference of the clusters exhibited a cell-
rich border region (Figure 2C, right, arrows). Staining
with the HABP probe showed that HA was found in the
tumours but at levels lower in mice treated with 4-MU
than in control mice (Figure 2E).
Knockdown of HAS3 expression in OSC1 cells is sufficient
to inhibit tumour progression and to mimic the
morphological stroma redistribution as caused by
systemic HAS inhibition
HAS3 is the major isoform in human ESCC as deter-
mined by real time RT-PCR and was correlated to EGFR
expression, perhaps pointing to the functional impor-
tance of HAS3 in ESCC. Because the systemic application
of 4-MU inhibits HA synthesis in both tumour cells and
stromal fibroblasts independently of the involved HAS
isoforms, the relative contribution and functional signifi-
cance of HA derived specifically from tumour cell asso-
ciated HAS3 was addressed. Transduction with shHAS3
lentivirus caused marked knockdown of HAS3 mRNA
and protein expression (Figure 3).
The subcutaneous injection of the shHAS3 transduced
OSC1 cells into nu/nu mice resulted in a marked inhibi-
tion of tumour growth (control 100 ± 57.7% vs. shHAS3
10.1 ± 5.3%, Figure 4A, B) and in a tumour morphology
strikingly similar to that seen after systemic inhibition of
HA synthesis. Specifically, tumours derived from
shHAS3-transduced OSC1 cells exhibited a phenotype
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densed cell-rich borders (Figure 4C, arrows) whereas the
morphology of control tumours was characterised by
numerous small clusters of OSC1 cells (Figure 4C, left).
Furthermore, alpha-smooth muscle actin staining
showed that stromal tissue was strongly pronounced in
shHAS3 tumours and separated the large OSC1 cell
clusters (Figure 4D). The lentiviral knockdown of HAS3
in the xenografted OSC1 cells resulted in reduced stro-
mal HA staining and in addition in pronounced associa-
tion of the residual HA with the circumference of
tumour cell clusters (Figure 4E). To identify the tumour
cells anti-human cytokeratin 18 (CK18) immunostaining
was performed in combination with HA staining (Figure
5). Strong stromal HA signals were detected in the
vicinity of CK18 positive tumour cell islands in shHAS3
xenografts (Figure 5B, arrows). However, within the
tumour cell clusters HA was less pronounced.
In combination, these findings indicate that 4-MU and
shHAS3 reduce the growth of OSC1-derived tumours in
nude mice, cause a transition to a more differentiated
tumour phenotype and cause formation of large tumour
cell clusters that were separated by pronounced stromal
tissue with reduced HA content.
Possible role of tumour cell CD44 for maintenance of
pericellular HA matrix in OSC1
Next, immunostaining was used to determine the
expression of the HA receptors CD44 and RHAMM in
response to treatment with 4-MU and shHAS3. The
Figure 1 HAS3 was upregulated and correlated with EGFR in human ESCC.( A) Real-time PCR of HAS3 mRNA from biopsy specimens from
normal mucosa (n = 13) and human ESCC differentiated into TNM staging (defining tumour size (T), lymph node involvement (N) and existence
of metastases (M)) (n = 20), mean ± SEM, *, p < 0.05. (B, C) EGFR expression was determined in the same biopsy specimens as in (A) and
correlated to HAS3 expression in normal mucosa (B) and in ESCC (C). HAS3 expression was significantly correlated to EGFR expression in ESCC.
(D) EGF stimulated HAS3 mRNA expression in the human ESCC cell line OSC1. This effect was rescued by use of the EGFR tyrosine kinase
inhibitor erlotinib and the molecular anti-EGFR antibody cetuximab. Data are mean ± SEM; n = 3-5; ***, p < 0.001.
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6 OSC1
cells, and tumour growth was monitored for 47 consecutive days. (A) Tumour volume as determined by calliper measurements; mean ± SEM, n
= 21 (control), 17 (4MU); *, p < 0.05. (B) Representative fpVCT images of control mice and 4-MU treated mice. Scale bars, 1 cm. Average tumour
volumes after sacrification of mice at the end of the experiment as measured by fpVCT showed a significant reduction in tumour volume in the
4-MU group. (C) Cryosections stained with H&E demonstrated a differentiated tumour phenotype in mice treated with 4-MU. This phenotype
was characterised by larger tumour cell clusters with a cell-rich border region (arrows) and pronounced tumour stroma. Scale bars, 200 μm. (D)
Stromal fibroblasts were stained with alpha-smooth muscle actin staining (red). Scale bars, 200 μm. (E) Hyaluronan staining (red) was associated
with both tumour cells and stromal tissue and was markedly reduced by treatment with 4-MU. Scale bars, 200 μm. Shown are representative
images of n = 6 (control) and n = 7 (shHAS3) experiments.
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tumour cells in controls and appeared to be redistribu-
ted and upregulated after 4-MU treatment in the
tumour cells that faced the stromal tissue (Figure 6A,
right). Similar changes in CD44 expression occurred in
the shHAS3 group compared to mice that received
OSC1 cells transduced with a control vector (Figure 6C,
right). RHAMM was strongly expressed in tumour cells
and to a weaker extent in stromal cells and did not
respond to 4-MU or shHAS3 (Figure 6B, D). Next we
considered that upregulated CD44 may bind stromal
HA to the tumour cell surface. To further examine this
possibility we compared CD44 and HA staining in
monoculture of OSC1 with OSC1 and fibroblast co-cul-
ture. In monocultures the lentiviral knockdown of
HAS3 resulted in an increased CD44 staining similar to
the in vivo results whereas the pericellular HA signal
was hardly detectable (Figure 7A, B). In contrast, in co-
cultures of fibroblasts and OSC1 cells, strong pericellu-
lar HA signals were obtained in controls (Figure 7C)
and were not diminished by knock down of HAS3 in
OSC1 (Figure 7D, arrows). These observations suggest
that HAS3 depleted OSC1 cells might utilise HA pro-
duced by stromal cells by means of increased CD44
expression to maintain the pericellular HA matrix.
Inhibition of proliferation
To address the underlying mechanisms for inhibition of
tumour progression, proliferation was determined by
immunostaining in the xenograft tumours. Immunos-
taining of the proliferation marker Ki67 revealed numer-
ous small clusters of proliferating tumour cells in the
controls. The proliferative activity was lower in speci-
mens treated with 4-MU than in controls and the prolif-
erating cells were confined to the outer circumference of
the large tumour cell clusters that tested positive for
HA, CD44 and RHAMM (Figure 8A; proliferating cells
in controls, 25% ± 3%; proliferating cells in sections of
mice treated with 4-MU, 15% ± 3%; p < 0.05; n = 4-5).
Subsequently the above described staining patterns
were compared to mice xenografted with shHAS3 trans-
duced OSC1 cells. The percentage of proliferating
tumour cells was lower in shHAS3-transduced tumours
compared to control tumours (Figure 8B: control, 35% ±
6%; shHAS3, 20% ± 2%; p < 0.05, n = 7). As observed
after 4-MU treatment, the remaining proliferative activ-
ity was confined to the CD44-positive circumference of
tumour cell islands. These results strongly support the
conclusion that inhibition of HAS3-mediated HA synth-
esis by OSC1, rather than HA synthesis by stromal cells,
is sufficient to inhibit ESCC proliferation and progres-
sion and to cause stromal remodelling into a more dif-
ferentiated tumour phenotype. In combination, tumour
cell specific knock down of HAS3 pheno-copied the
effect of systemic inhibition of HA synthesis.
Discussion
HA synthesis is not sufficient for malignant transforma-
tion [30], but HA-binding proteins and HA receptors
provide a matrix environment that supports the malig-
nant phenotype of cancer cells, stromal cell recruitment,
and, thus, the progression of cancer [31]. Recently, the
importance of stromal HA-binding proteins was demon-
strated for the proteoglycan versican, which triggers the
invasion and retention of inflammatory cells in Lewis
lung carcinoma and supports metastasis [17]. In human
ESCC, HA accumulates in the parenchyma and stroma,
and HA is produced by both tumour cells and stroma
[22,28]. The amount of HA, which is supposed to be
initially high in ESCC, decreases with progression to
undifferentiated aggressive carcinomas; this finding sug-
gests increased turnover [32].
Amount of HA and distribution are important prog-
nostic factors in a variety of tumour types. However,
important differences exist between tumours that origi-
nate from different types of tissue. Tumours arising
from simple epithelia such as lung [33], gastric [34], sali-
vary gland [35] and from the thyroid epithelium [36]
show a strong correlation between tumour stage and
increased HA content. In contrast, those derived from
Figure 3 Lentiviral knockdown of HAS3 in OSC1 cells.T h e
transduction with lentiviral shHAS3 results in (A) a strong decrease
of HAS3 mRNA without affecting HAS2 mRNA levels. (B)A
significant reduction of HAS3 protein levels was found. Shown are
the results of three independent RT-PCR experiments and a
representative immunoblot of HAS3 with quantitative analysis of n
= 3 experiments, mean ± SEM, ** p < 0.01, *** p < 0.001.
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(A) Nude mice received subcutaneous injections of 10
6 OSC1 cells that had been transduced in vitro with a lentivirus containing either
scrambled shRNA (control) or shHAS3. Tumour growth as assessed by calliper measurements; mean ± SEM, n = 6 (control), 7 (shHAS3); *, p <
0.05. (B) Representative fpVCT images of mice after 65 days. Average tumour volumes after sacrification of mice at the end of the experiment as
measured by fpVCT showed also a significant reduction in tumour volume in the shHAS3 group. (C) H&E revealed changes in tumour
morphology strikingly similar to those after 4-MU (compare Figure 2). (D) Tumour stroma was visualised by alpha-smooth muscle actin staining
(red). (E) Xenografting shHAS3 tumour cells caused redistributed hyaluronan staining specifically localised to the outer layer of tumour cell
clusters. Scale bars, 200 μm. Shown are representative images of n = 6 (control) and n = 7 (shHAS3) experiments.
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skin epithelium are characterized by an increase in HA
abundance in early tumour stages which decreases in
high grade poorly differentiated tumour stages [22,32].
In line with this, a tendency to increased HAS3 levels in
t h eT=1s t a g ec o m p a r e dt oT=2 - 4s t a g e sw a sa l s o
seen in the present work (Figure 1A) although this was
not significant.
The experiments reported here were performed to
further increase our understanding about the role of HA
synthesis in the progression of human ESCC, to evaluate
the therapeutic potential of pharmacologic inhibition of
HA synthesis for this tumour type and to attempt to dif-
ferentiate the roles of tumour cell derived HA versus
stromal cell-derived HA. Therefore, we analysed the
response of ESCC xenografts to systemic versus tumour
cell-targeted interference with HA synthesis. The inhibi-
tion of ESCC xenograft tumours by 4-MU is in line
with reports showing that 4-MU has anti-tumour activ-
ity: it inhibits liver metastasis of melanoma cells; sensi-
tises pancreatic cancer cells to gemcitabine and breast
cancer cells to trastuzumab treatment in mice; and
decreases prostate cancer cell growth in a xenograft
model [11-14]. However, this is the first demonstration
that inhibition of a specific HAS isoform, HAS3, in
tumour cells is as efficient as systemic HAS-inhibition
by 4-MU.
Specifically, a more differentiated tumour phenotype,
pronounced stromal strands, fewer singular tumour cells
and reduced proliferation were observed. This in vivo
phenotype shows strong similarities to the phenotype
observed in vitro after treatment with 4-MU or shHAS3:
specifically in vitro formation of tumour cell clusters
with smooth cell borders occurred in response to inhibi-
tion of HA synthesis [24]. After knock down of HAS3
xenografted OSC1 cells still exhibited strong pericellular
HA staining concomitant with pronounced CD44 stain-
ing suggesting that the elevated CD44 expression may
cause binding of stroma derived HA to the tumour cell
surface. The recruitment of stromal HA in response to
knock down of HAS3 by tumour cells might be part of
a compensatory mechanism. This thesis is corroborated
by reports that melanoma cells stimulate stromal HA
production by soluble factors to facilitate tumour
Figure 5 Detection of the distribution of HA in shHAS3 knockdown xenografts by double staining for tumour cells (CK18) and HA.
Section from the same series as in Figure 3 were double stained for HA (red) and CK18 (green) to determine the exact location of HA in the
xenograft tumour sections. (A) Scrambled control sections revealed a strong HA signal in tumour and stroma. (B) HA staining in shHAS3 samples
showed a strong signal in the stroma and tumour/stroma interface (arrows). However, HA was much less pronounced within the tumour cell
clusters. Scale bars, 30 μm. Shown are representative images of n = 6 (control) and n = 7 (shHAS3) experiments.
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Page 9 of 14growth and invasion [37] and lung carcinoma cells using
stimulatory membrane-bound glycoproteins to support
locomotion and adhesion [38]. Functionally, the HA/
CD44 interactions might contribute to tumour cell pro-
liferation, because after inhibition of HA synthesis by 4-
MU or application of shRNA targeting HAS3 the
remaining proliferative activity of tumour cells was con-
fined to the CD44 positive tumour cell - stroma inter-
face. The interaction between tumour cells and stromal
fibroblasts mentioned above [38] might play an
Figure 6 Expression of CD44 and RHAMM in response to 4-MU versus shHAS3.( A) 4-MU, immunostaining of human CD44 (red) revealed
that CD44 was redistributed to the interface between tumour cells and stroma in response to 4-MU. (B) 4-MU, RHAMM was detected in both
OSC1 cells and stromal cells. (C) shHAS3, shHAS3 transduction of tumour cells caused a similar redistribution of human CD44 (red) to the
tumour-stroma interface. (D) shHAS3, RHAMM (red) was detected in both shHAS3 transduced OSC1 and stromal cells. Scale bars, 200 μm. Shown
are representative images of n = 6 (control) and n = 7 (shHAS3) experiments.
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Page 10 of 14important role in this counterregulatory mechanism
under HA deprived conditions as it was shown for
breast carcinomas that the tumour-adjacent stroma
showed elevated levels of HA and hyaluronectin to
facilitate invasion [39]. However, despite the utilisation
of stromal HA the current findings clearly showed that
tumour cell mediated HA synthesis is critical in this
model of ESCC.
Figure 7 Co-culture of OSC1 cells and fibroblasts suggested binding of stromal HA to the tumour cell surface via CD44.O S C 1c e l l s
were cultured alone and with fibroblasts to gain mechanistic insight into the origin of OSC1-bound HA in shHAS3 transduced OSC1 cells. (A)I n
monoculture OSC1 cells showed a strong staining for HA (green) and a weak signal for CD44 (red). (B) Transduction with shHAS3 strongly
decreased HA deposition (green) and increased CD44 expression (red, arrows). (C) In co-cultures OSC1 cells exhibited similar pericellular HA as
compared to controls in A. (D) In contrast shHAS3 transduced OSC1 cell still exhibited a strong pericellular HA signal (green, arrows) in the
presence of fibroblasts that co-localized with increased CD44 (red, arrows). Scale bars, 10 μm. Shown are representative images of n = 3.
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ted after both interventions. The previous characterisa-
tion of the molecular mechanisms underlying the
inhibition of malignant ESCC phenotype by interference
with HA synthesis in vitro suggested that both RHAMM
and CD44 signalling are critically involved in the prolif-
erative and migratory phenotype of ESCC [24] through
activation of focal adhesion signalling and MAPK signal-
ling. The abundant expression of RHAMM and the
redistribution of CD44 upon treatment in xenograft
tumours are therefore in line with the proposed role of
RHAMM and CD44 in transducing the effects of HA in
this model. In addition, in prostate carcinoma HAS3
and HAS2 have been shown to produce HA that is bro-
ken down by Hyal1 and that subsequently drives tumour
progression and even metastasis [5,40,41]. Therefore,
degradation of the high molecular weight HA into smal-
ler fragments may contribute to tumour progression in
ESCC and should be investigated in future studies.
Remarkably, the EGF receptor (EGFR, ErbB1) is over-
expressed in 40% to 90% of ESCC tumours and overex-
pression of EGFR is associated with a poor prognosis
[42,43]. As we show here, EGFR expression is positively
correlated with HAS3 expression in human ESCC. Of
note, a steeper correlation between HAS3 and EGFR
levels was found in the subgroup of T = 1 tumours,
which possibly suggests a stronger dependence of this
early tumour stage on EGF stimulated HAS3 expression.
In line with this finding, EGF receptor activation led to
induction of HAS3 in ESCC. Induction of HAS3 expres-
sion by EGF and ErbB2 receptors has also been shown
for keratinocytes, prostate and lung carcinoma cells
[44-47]. Therefore, EGF may be an important regulator
of HAS3 expression in ESCC, which would be especially
relevant in cancers known to be responsive to EGF inhi-
bition, such as head and neck squamous cell carcinoma
and metastatic colorectal cancer.
On the other hand, HA has been shown to contribute to
the EGFR pathway via HA-CD44 interaction. HA-CD44
complexes colocalize and potentially transactivate the EGF
receptor leading to phosphorylation of ERK1 and ERK2 in
glioblastoma cell lines [48] and to increase tumour growth,
migration and resistance to a variety of chemotherapeutic
drugs such as methotrexate, doxorubicin, adriamycin and
cisplatin in head and neck cancer [49]. In line with this,
reduction of HA synthesis by 4-MU enhances the antican-
cer activity of gemcitabine in pancreatic cancer cells [12].
Consistently, adding exogenous HA leads to increased
resistance to the EGFR inhibitor gefitinib in non small
lung cancer cells [47]. However, vice versa, EGFR was also
Figure 8 Effects of 4-MU and tumour cell targeted shHAS3 on proliferation in OSC1 xenografts.( A) 4-MU, staining of human Ki67 (red)
was markedly reduced by 4-MU treatment and confined to the interface between tumour cells and stroma. (B) shHAS3, staining of human Ki67
(red) was markedly reduced in tumour cells transduced with shHAS3. Scale bars 200 μm. Shown are representative images of n = 6 (control) and
n = 7 (shHAS3) experiments.
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of genes associated with cellular invasion and proliferation
i.e. plasminogen activator inhibitor-1 (PAI-1) or tissue
inhibitor of metalloproteinases (TIMP-1) in glioblastoma
cell lines [48]. Moreover, in corneal epithelial cells, it was
shown that HA and EGFR effects on migration were addi-
tive and that inhibition of either HA or EGFR signalling
could not completely abolish the combined effects. This
observation might indicate additional independent actions
of EGFR and HA-CD44 [50]. Taken together, these reports
show a close interrelationship between EGFR and HA-
CD44 pathways and possibly a positive regulatory feedback
in which EGF induces HA production which in turn
amplifies the EGFR dependent signalling via CD44. There-
fore, therapeutic modulation of the HA system may contri-
bute new anticancer strategies in tumours dependent on
EGFR signalling by disruption of this feedback cycle.
Conclusions
In summary the present data extend the results from
cell culture experiments [24] to in vivo growth of
human oesophageal xenograft tumours. Specifically, it is
proposed that ESCC tumour cells overexpress HAS3 in
an EGFR dependent manner and that this overexpres-
sion supports a dedifferentiated proliferative tumour cell
phenotype. Therefore, pharmacologic inhibition of HA
s y n t h e s i sm a yp r o v i d ean o v el therapeutic target for
ESCC.
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